ONCOZENE MICROSPHERES 40UM, 2ML, ONCOZENE MICROSPHERES 75UM, 2ML, ONCOZENE MICROSPHERES 100UM, 2ML, ONCOZENE MICROSPHERE

K130307 · Celonova Biosciences, Inc. · KRD · Mar 4, 2013 · Cardiovascular

Device Facts

• Record ID: K130307
• Device Name: ONCOZENE MICROSPHERES 40UM, 2ML, ONCOZENE MICROSPHERES 75UM, 2ML, ONCOZENE MICROSPHERES 100UM, 2ML, ONCOZENE MICROSPHERE
• Applicant: Celonova Biosciences, Inc.
• Product Code: KRD · Cardiovascular
• Decision Date: Mar 4, 2013
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 870.3300
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

ONCOZENE™ Microspheres are intended for embolization of hypervascular tumors and arteriovenous malformations.

Device Story

ONCOZENE™ Microspheres are precise, soft, deformable, opaque microspheres used to occlude vasculature; intended to block blood flow to hypervascular tumors (HVT) or arteriovenous malformations (AVM). Manufactured from sodium polymethacrylate and coated with Polyzene®-F; supplied sterile in polycycloolefin syringes. Delivered via catheter by clinicians to target tissue. Microspheres are compressible to facilitate smooth delivery. By physically occluding vessels, the device restricts blood flow to the target lesion, providing a therapeutic benefit for tumor and malformation management.

Clinical Evidence

No clinical data generated specifically for this device. Evidence relies on a literature review of 1,029 abstracts regarding Transarterial Embolization (TAE) and post-market surveillance data from over 70,000 units of the predicate device distributed worldwide. Literature supports the safety and effectiveness of small (40 µm and 100 µm) microspheres for treating hypervascularized tumors and arteriovenous malformations.

Technological Characteristics

Materials: Sodium polymethacrylate microspheres coated with Polyzene®-F. Dimensions: 40±10μm, 75±15μm, 100±25μm diameters. Energy: None (passive mechanical occlusion). Connectivity: None. Sterilization: Sterile, pyrogen-free. Packaging: 20ml polycycloolefin syringes with 7ml total fill volume.

Indications for Use

Indicated for the embolization of hypervascular tumors and arteriovenous malformations in patients requiring vascular occlusion.

Regulatory Classification

Identification

A vascular embolization device is an intravascular implant intended to control hemorrhaging due to aneurysms, certain types of tumors (e.g., nephroma, hepatoma, uterine fibroids), and arteriovenous malformations. This does not include cyanoacrylates and other embolic agents, which act by polymerization or precipitation. Embolization devices used in neurovascular applications are also not included in this classification, see § 882.5950 of this chapter.

Special Controls

*Classification.* Class II (special controls.) The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices.” For availability of this guidance document, see § 870.1(e).

Predicate Devices

• Embozene Microspheres (K073417)

Submission Summary (Full Text)

{0}------------------------------------------------

K 130307

## MAR 0 4 2013

#### 510(k) Summary of Safety and Effectiveness

| Summary Date: | February 5, 2013 |
|---------------|----------------------------------------------------------------------------------------------------------------------|
| Submitter: | CeloNova BioSciences, Inc.<br>18615 Tuscany Stone<br>San Antonio, TX 78258<br>Fax: [phone]<br>Fax: [phone] |
| Contact : | Nicole C. Barber<br>Sr. Regulatory Specialist |

#### 1. Common name, Trade name & Classification

Trade Name: ONCOZENE™ Microspheres Common Name & Codes: Vascular Embolization device, embolization, arterial (21CFR 870.3300, product code KRD)

#### 2. 510(k) Number and Product code of predicate device

| Trade Name: | Embozene Microspheres |
|----------------|---------------------------|
| Manufacturer: | CeloNova BioSciences, Inc |
| 510(k) number: | K073417 |
| Product code : | KRD, 21 CFR 870.3300 |

#### 3. Indications for Use and Intended Purpose

ONCOZENE™ Microspheres are intended for embolization of hypervascular tumors and arteriovenous malformations.

#### 4. Device Description

ONCOZENE™ Microspheres are precise dimensioned, soft, deformable microspheres intended to occlude vasculature for the purpose of blocking blood flow to a target tissue such as hypervascular tumor (HVT) or arteriovenous malformation (AVM). ONCOZENE™ Microspheres are manufactured from sodium polymethacrylate and coated with proprietary Polyzene®-F. The fully polymerized microspheres are compressible to enable smooth delivery through the indicated delivery catheter. ONCOZENE™ Microspheres contain no added dyes and are visually opaque.

{1}------------------------------------------------

## 510(k) Summary of Safety and Effectiveness (continued)

ONCOZENE™ Microspheres are supplied sterile and packaged in 20ml polycycloolefin syringes with a standard 7ml fill volume across the range. Available as 40μm, 75μm and 100μm microsphere diameter sizes, the ONCOZENE™ syringes are available with 2ml or 3ml microsphere volume per syringe. The product configurations are shown in the Table below.

| Product REF Codes | | Volume of ONCOZENE™ Microspheres per syringe | |
|--------------------------------------|---------------|----------------------------------------------|------------------|
| | | 2ml microspheres | 3ml microspheres |
| ONCOZENE™<br>Microsphere<br>diameter | 40 μm ±10 μm | 10420-US1 | 10430-US1 |
| | 75 μm ±15 μm | 10720-US1 | 10730-US1 |
| | 100 μm ±25 μm | 11020-US1 | 11020-US1 |

### 5. Similarities and Differences to Predicate device

The intended use of ONCOZENE™ Microspheres and the predicate are equivalent. ONCOZENE™ Microspheres and the predicate device have the same design, specifications, fundamental scientific technology, and packaging.

The pH range of ONCOZENE™ Microspheres is more tightly controlled than the predicate but within the existing specification cleared for the predicate. Minor process changes have been made to achieve the tighter control of the pH range.

The predicate device is available in 1ml and 2ml microsphere volume per syringe. ONCOZENE™ Microspheres are available in 2ml and 3ml microsphere volume per syringe.

The predicate device is available sizes 40μm, 75μm, 400μm, 400μm, 500μm, 700μm, and 900μm. ONCOZENE™ Microspheres are available in sizes 40μm, 75μm, and 100μm.

{2}------------------------------------------------

## 6. Summary of Technological Characteristics

| Point of Comparison | Predicate | ONCOZENE™ |
|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
| Chemical composition | unchanged | unchanged |
| Osmolarity of transport solution | unchanged | unchanged |
| pH of transport solution | pH of transport solution is tighter for ONCOZENE than predicate but within existing specification for cleared predicate | pH of transport solution is tighter for ONCOZENE than predicate but within existing specification for cleared predicate |
| Size Range | $40 \pm 10 \mu m$<br>$75 \pm 15 \mu m$<br>$100 \pm 25 \mu m$<br>$250 \pm 50 \mu m$<br>$400 \pm 50 \mu m$<br>$500 \pm 50 \mu m$<br>$700 \pm 50 \mu m$<br>$900 \pm 75 \mu m$ | $40 \pm 10 \mu m$<br>$75 \pm 15 \mu m$<br>$100 \pm 25 \mu m$ |
| Color Code | Color or opaque | Opaque |
| Sterility | Pyrogen-free, sterile | Pyrogen-free, sterile |
| Packaging | Syringe or vial | Syringe |
| Syringe total fill volume | 7ml | 7ml |
| Microsphere volume per syringe | 1 or 2 ml | 2 or 3 ml |
| Shelf life | unchanged | unchanged |
| Indication for Use | unchanged | unchanged |

Comparison between predicate (Embozene®) and ONCOZENE™Microspheres

## 7. Summary of In-Vitro Testing

The ONCOZENE™ Microspheres are a variant within the existing specification cleared for the predicate device. The minor changes made to the manufacturing processes to achieve tightened control of pH have not led to additional testing requirements.

## 8. Summary of Clinical Experience

The clinical evaluation included in the 510(k) reviews experience over the last ten years with Transrterial Embolization (TAE) using various embolic agents to physically occlude vessels to restrict blood flow. The evaluation looks at 1029 abstracts from the PubMed search including the predicate device and other embolic devices and reviews CeloNova's adverse event data resulting from in excess of 70,000 units distributed worldwide.

The overall review of the scientific literature and post market surveillance, indicate that embolization of tumors with small (40 µm and 100 µm) microspheres (Embozene® Microspheres) remain safe and effective for the treatment of hypervascularized tumors and arteriovenous malformations. Therefore, it could be concluded that the benefits of TAE with Embozene microspheres family including the

{3}------------------------------------------------

## 510(k) Summary of Safety and Effectiveness (continued)

ONCOZENE™ Microspheres for the treatment of hypervascular tumors and arteriovenous malformations outweigh the potential risk when used within their labeled application.

#### 9. Summary

ONCOZENE™ Microspheres are essentially equivalent to the predicate device Embozene Microspheres (K073417) but with a tighter controlled pH range (within the existing cleared specification). ONCOZENE™ Microspheres and the predicate device have indications for use, design, specifications, fundamental scientific technology, and packaging.

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three stripes forming its body and wing. The eagle is facing right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

March 4, 2013

CeloNova Biosciences, Inc. C/O Nicole C. Barber 18615 Tuscany Stone Suite 100 San Antonio, Texas 78258

Re: K130307

.

Trade/Device Name: ONCOZENE™ Microspheres Regulation Number: 21 CFR 870.3300 Regulation Name: Vascular Embolization Device Regulatory Class: Class II Product Code: KRD Dated: February 6, 2013 Received: February 7, 2013

Dear Ms. Barber:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

{5}------------------------------------------------

Page 2 - Nicole C. Barber

forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

## Matthew G. Hillebrenner

for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{6}------------------------------------------------

#### Indications for Use Statement

510(k) Number (if known) K130307

Device Name

Vascular Embolization Device

Indications for Use

ONCOZENE™ Microspheres are indicated for the embolization of hypervascular tumors and arteriovenous malformations.

Prescription Use_ × (Per 21 CFR 801. 109) AND/ OR

Over-The-Counter Use_

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of CDRH, Office of Device Evaluation (ODE)

# Matthew GN Willebrenner